Serum Interleukin-37 Levels in Patients with Systemic Sclerosis and its Relation with Clinical Findings

Turgut Bozan; Remzi Cevik; İbrahim Batmaz; İbrahim Gündüz; Abdullah Zübeyir Dagli

doi:10.5798/dicletip.1266709

Serum Interleukin-37 Levels in Patients with Systemic Sclerosis and its Relation with Clinical Findings

Abstract

Aim: This study investigates serum interleukin(IL)-37 levels in patients with systemic sclerosis (SS) and assesses its relationship with clinical findings. Methods: This study included 35 patients with SS and 30 healthy control subjects. The demographic and clinical characteristics of the patients, such as the presence of Raynaud’s phenomenon, SS subtype, digital ulcers, gastrointestinal and lung involvement, and disease activity, were recorded. The medications used by the patients were recorded, and Serum IL-37 levels were measured using an enzyme-linked immunosorbent assay. The United Kingdom Functional Scoring system was used to evaluate the functional status of the patients, while the Valentini criteria were used to evaluate disease activity. Skin involvement was evaluated based on the modified Rodnan skin score. Results: Although serum IL-37 levels were found to be lower in patients with SS than in the control group, the difference was not statistically significant (p= 0.078). A negative correlation was identified between serum IL-37 levels and C3 levels in patients with SS (p= 0.046). No significant relationship was found between IL-37 levels and other clinical and laboratory parameters. Conclusion: Unlike in patients with autoimmune disorders, serum IL-37 levels were found to be lower in patients with SS than in the control subjects, and IL-37 demonstrated a negative correlation with C3 levels.

Keywords

References

1. Cutolo M, Soldano S, Smith V.Pathophysiology of systemic sclerosis: current understanding and new insights. Expert Rev ClinImmunol. 2019;15(7):753-64.
2. Koca SS, Ozgen M, Isik A. Sistemik skleroz etiyopatogenezi. RAED Dergisi.2012;4:39-46.
3. Asano Y. Systemic sclerosis J Dermatol. 2018;45(2):128-38.
4. Denton CP, Khanna D.Systemic sclerosis. Lancet. 2017;390(10103):1685-99.

Details

Primary Language

Turkish

Subjects

Health Care Administration

Journal Section

Research Article

Authors

Turgut Bozan ^* This is me
Türkiye

Remzi Cevik This is me
Türkiye

İbrahim Batmaz This is me
Türkiye

İbrahim Gündüz This is me
Türkiye

Abdullah Zübeyir Dagli This is me
Türkiye

Publication Date

March 19, 2023

Submission Date

October 12, 2022

Acceptance Date

February 28, 2023

Published in Issue

Year 2023 Volume: 50 Number: 1

DOI

https://doi.org/10.5798/dicletip.1266709

IZ

https://izlik.org/JA82UZ55DT

Cite

RIS / Bibtex

APA

Bozan, T., Cevik, R., Batmaz, İ., Gündüz, İ., & Dagli, A. Z. (2023). Serum Interleukin-37 Levels in Patients with Systemic Sclerosis and its Relation with Clinical Findings. Dicle Medical Journal, 50(1), 37-43. https://doi.org/10.5798/dicletip.1266709

AMA

1.Bozan T, Cevik R, Batmaz İ, Gündüz İ, Dagli AZ. Serum Interleukin-37 Levels in Patients with Systemic Sclerosis and its Relation with Clinical Findings. Dicle Medical Journal. 2023;50(1):37-43. doi:10.5798/dicletip.1266709

Chicago

Bozan, Turgut, Remzi Cevik, İbrahim Batmaz, İbrahim Gündüz, and Abdullah Zübeyir Dagli. 2023. “Serum Interleukin-37 Levels in Patients With Systemic Sclerosis and Its Relation With Clinical Findings”. Dicle Medical Journal 50 (1): 37-43. https://doi.org/10.5798/dicletip.1266709.

EndNote

Bozan T, Cevik R, Batmaz İ, Gündüz İ, Dagli AZ (March 1, 2023) Serum Interleukin-37 Levels in Patients with Systemic Sclerosis and its Relation with Clinical Findings. Dicle Medical Journal 50 1 37–43.

IEEE

[1]T. Bozan, R. Cevik, İ. Batmaz, İ. Gündüz, and A. Z. Dagli, “Serum Interleukin-37 Levels in Patients with Systemic Sclerosis and its Relation with Clinical Findings”, Dicle Medical Journal, vol. 50, no. 1, pp. 37–43, Mar. 2023, doi: 10.5798/dicletip.1266709.

ISNAD

Bozan, Turgut - Cevik, Remzi - Batmaz, İbrahim - Gündüz, İbrahim - Dagli, Abdullah Zübeyir. “Serum Interleukin-37 Levels in Patients With Systemic Sclerosis and Its Relation With Clinical Findings”. Dicle Medical Journal 50/1 (March 1, 2023): 37-43. https://doi.org/10.5798/dicletip.1266709.

JAMA

1.Bozan T, Cevik R, Batmaz İ, Gündüz İ, Dagli AZ. Serum Interleukin-37 Levels in Patients with Systemic Sclerosis and its Relation with Clinical Findings. Dicle Medical Journal. 2023;50:37–43.

MLA

Bozan, Turgut, et al. “Serum Interleukin-37 Levels in Patients With Systemic Sclerosis and Its Relation With Clinical Findings”. Dicle Medical Journal, vol. 50, no. 1, Mar. 2023, pp. 37-43, doi:10.5798/dicletip.1266709.

Vancouver

1.Turgut Bozan, Remzi Cevik, İbrahim Batmaz, İbrahim Gündüz, Abdullah Zübeyir Dagli. Serum Interleukin-37 Levels in Patients with Systemic Sclerosis and its Relation with Clinical Findings. Dicle Medical Journal. 2023 Mar. 1;50(1):37-43. doi:10.5798/dicletip.1266709